SKIDA1

Across TCGA pan-cancer cohorts, SKIDA1 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated SKIDA1 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SKIDA1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SKIDA1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, CESC, and THYM are the cancer types where SKIDA1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	48	view →
CESC	DFS	Median	II,III,IV	0.053	0.786	<.001	30	view →
THYM	DFS	Median	II,III,IV	0.172	0.747	.005	12	view →
BRCA	OS	Median	II,III,IV	0.110	0.565	.002	12	view →
HNSC	OS	Median	III,IV	0.157	0.658	.001	12	view →
LUAD	OS	Median	All	0.156	0.788	<.001	12	view →
LIHC	OS	Median	All	0.098	0.774	.001	9	view →
UCEC	DFS	Median	II,III,IV	0.928	0.480	.027	8	view →
ESCA	DFS	Median	All	0.240	0.542	.017	6	view →
PRAD	DFS	Median	All	0.205	0.779	.001	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

SKIDA1–SCLC (OS)

Open the SCLC breakdown →